Relay Therapeutics, a leader in cutting-edge approaches to drug discovery, utilised X-Chem’s DNA-Encoded Library (DEL) platform to perform hit finding intended to discover molecules with differentiated pharmacological properties.
The resulting molecule led to a development candidate — a milestone under the companies’ collaboration agreement and to progress in evaluation.
“Relay Therapeutics is an incredibly innovative company with a unique approach to drug discovery,” said X-Chem CEO Matt Clark.
“We are immensely proud that our collaboration was able to provide a compelling starting point for Relay Therapeutics’ drug discovery campaign that led to a development candidate. We look forward to seeing Relay bring these innovations forward to the benefit of patients.”
